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White matter hyperintensity reduction
and outcomes after minor stroke
ABSTRACT
Objective: To assess factors associated with white matter hyperintensity (WMH) change in a large
cohort after observing obviousWMH shrinkage 1 year after minor stroke in several participants in
a longitudinal study.
Methods: We recruited participants with minor ischemic stroke and performed clinical assess-
ments and brain MRI. At 1 year, we assessed recurrent cerebrovascular events and dependency
and repeated the MRI. We assessed change in WMH volume from baseline to 1 year (normalized
to percent intracranial volume [ICV]) and associations with baseline variables, clinical outcomes,
and imaging parameters using multivariable analysis of covariance, model of changes, and multi-
nomial logistic regression.
Results: Among 190 participants (mean age 65.3 years, range 34.3–96.9 years, 112 [59%]
male), WMH decreased in 71 participants by 1 year. At baseline, participants whose WMH
decreased had similar WMH volumes but higher blood pressure (p 5 0.0064) compared with
participants whose WMH increased. At 1 year, participants with WMH decrease (expressed as
percent ICV) had larger reductions in blood pressure (b 5 0.0053, 95% confidence interval [CI]
0.00099–0.0097 fewer WMH per 1–mm Hg decrease, p 5 0.017) and in mean diffusivity in
normal-appearing white matter (b 5 0.075, 95% CI 0.0025–0.15 fewer WMH per 1-unit mean
diffusivity decrease, p 5 0.043) than participants with WMH increase; those with WMH increase
experienced more recurrent cerebrovascular events (32%, vs 16% with WMH decrease, b 5
0.27, 95% CI 0.047–0.50 more WMH per event, p 5 0.018).
Conclusions: SomeWMHmay regress after minor stroke, with potentially better clinical and brain
tissue outcomes. The role of risk factor control requires verification. Interstitial fluid alterations
may account for some WMH reversibility, offering potential intervention targets. Neurology®
2017;89:1003–1010
GLOSSARY
ANCOVA 5 analysis of covariance; BP 5 blood pressure; CI 5 confidence interval; DTI 5 diffusion tensor imaging; ICV 5
intracranial volume; IQR 5 interquartile range; MD 5 mean diffusivity; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke
Scale; Q 5 quintile; SVD 5 small vessel disease; WMH 5 white matter hyperintensities.
White matter hyperintensities (WMH) are a common feature of cerebral small vessel disease
(SVD) on brain MRI.1 Among several adverse clinical effects, WMH are associated with
worsening cognition, double the risk of dementia, and triple the risk of stroke.2 A high
WMH burden, vascular risk factors (particularly hypertension), and increasing age are associated
with WMH,3 but other factors that influence WMH formation or longitudinal change remain
poorly understood.
Most longitudinal studies focused on WMH progression, which, in population studies,
usually occurs gradually.3 WMH reduction was reported in only 1 case report4 and in 14%
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of patients with stroke in a small case series,5
but those studies did not comment on any
clinical effect or contemporaneous changes on
other MRI parameters to provide confidence
that the WMH reduction was not artifactual.
In a prospective study of clinical and imag-
ing outcomes at 1 year after minor ischemic
stroke,6 we unexpectedly observed visible
reductions in the extent of WMH in some
participants (figure 1). Therefore, here, we
analyzed the proportions of participants with
an increase, no change, or a decrease in WMH
and determined whether WMH change was
associated with recurrent cerebrovascular
events, functional outcome, or changes in
other imaging parameters.
Figure 1 Examples of WMH reduction in 2 participants
MRIs from patients (A, top and B, bottom) who showed definite visible reduction in WMH on MRIs between presentation
with minor stroke (left, baseline; inset, the acute index infarct [arrow] on MRI diffusion tensor imaging) and 1 year (right).
Note also the increase in visibility of sulci at 1 year (arrowheads, B, bottom right), indicating a reduction in brain volume
accompanying the reduction in WMH volume. FLAIR 5 fluid-attenuated inversion recovery; WMH 5 white matter
hyperintensities.
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METHODS Study design, participants, classification.
We recruited, prospectively and as consecutively as possible, pa-
tients who presented within 4 weeks of minor ischemic stroke
of lacunar or cortical subtype to our regional stroke service
between May 1, 2010, and May 31, 2012, as described previ-
ously.6,7 The regional stroke service is provided by a team of
dedicated stroke physicians and specialists covering inpatients
and outpatients, acute treatment, and secondary prevention.
We focused the present analysis on participants who had brain
MRI at presentation and at 1 year after stroke to assess WMH
change. We included participants$18 years of age who were able
to provide consent and excluded patients with moderate to severe
stroke (NIH Stroke Scale [NIHSS] score .7), MRI contraindi-
cations, and hemorrhagic stroke.
All participants were assessed by a specialist stroke physician
at presentation as part of their clinical stroke management and
at recruitment to the study for research purposes. We recorded
symptoms, medical history, vascular risk factors (diagnosis of
hypertension, diabetes mellitus, hyperlipidemia, smoking status,
blood pressure [BP]), medications, and alcohol use, and we per-
formed a full clinical examination. We assessed NIHSS, BP (sit-
ting, automated cuff, Omron Corp, Kyoto, Japan), and carotid
stenosis (color Doppler ultrasound imaging) and performed
ECG and blood and urine analyses.7
All participants underwent structural and brain diffusion ten-
sor imaging (DTI) at presentation to confirm the acute index
infarct. Participants with clinically definite stroke but no DTI-
visible lesion were included if no alternative explanation for stroke
symptoms was found. We assigned a definitive stroke subtype
(lacunar or cortical) using the Oxfordshire Community Stroke
Project Classification clinical syndrome8 and MRI DTI findings
(recent small subcortical or cortical infarct).9 If no DTI lesion was
visible (as occurs in 30% of minor strokes10), the clinical subtype8
was used.
All participants received treatment according to UK guide-
lines: antiplatelet drugs (mostly CLOPIDOGREL), a statin
(mostly simvastatin), antihypertensive drugs (target 130 mm
Hg systolic), and oral anticoagulants for atrial fibrillation. In addi-
tion, they were encouraged to stop smoking, to exercise, to reduce
their salt intake, and to watch their weight.
Follow-up. We assessed all participants at 1 year after stroke, in
person, for dependency (modified Rankin Scale [mRS] using
a structured assessment tool), recurrent stroke or TIA, vascular
risk factors, and BP, and we repeated the MRI. All clinical assess-
ments were masked to imaging and vice versa.
MRI studies. All MRI examinations were performed on the
same MRI scanner (1.5T Signa HDxt, General Electric, Milwaukee,
WI) with self-shielding gradients and an 8-channel phased-array
head coil. MRI included DTI, fluid-attenuated inversion recov-
ery, T2-weighted, T2*- and T1-weighted volume sequence
(published protocol,7 table e-1 at Neurology.org). Daily quality
assurance tests were performed to maintain scanner uniformity.
Image analysis. Visual. We defined the infarct responsible for
the presenting symptoms as index, old infarcts present at baseline
as old, and infarcts occurring between presentation and 1 year as
incident. Index infarcts were identified as hyperintense on DTI/
hypointense on apparent diffusion coefficient maps and/or hyper-
intense on fluid-attenuated inversion recovery, T2-weighted, and
hypointense on T1-weighted images, possibly with minor mass
effect but no ex vacuo effect.9 Small subcortical infarcts9 were
rounded or ovoid,,2 cm in diameter in subcortical gray or white
matter. Cortical infarcts involved cortex.8 Older infarcts were
identified by shape, ex vacuo effect, and typical malacic signal
characteristics. We categorized WMH using the Fazekas score.11
We assessed 1-year imaging first blinded to baseline and then
comparing 1-year imaging with baseline to identify incident in-
farcts and hemorrhages and to score WMH change visually using
the Prins WMH Change score.12
Computational.We registered all structural images to the T1
sequence (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FLIRT).13 An
experienced analyst, blinded to clinical details, used a validated
multispectral method (www.sourceforge.net/projects/bric1936)
to measure intracranial volume (ICV) and whole-brain and
WMH volumes and separated index/old/incident infarcts from
WMH manually to avoid errors in WMH volume.14 We stan-
dardized brain and WMH volumes to ICV (expressed as per-
centage of ICV). We registered WMH maps to DTI images
nonlinearly15 to measure mean diffusivity (MD) and fractional
anisotropy in WMH and normal-appearing white matter. By
the above method, the mean difference in WMH volume on
repeated measures was 0.712 mL (95% CI 24.451 to 3.028)
for a mean WMH volume of 21.96 6 24.84 mL.
Statistical analysis. We assessed differences between partici-
pants with MRI at baseline and 1 year (the present analysis)
and those who did not have MRI at 1 year.
We combined deep and periventricular Fazekas scores into
a total WMH score (0–6). We combined clinically evident recur-
rent stroke or TIA and incident infarct on imaging into a com-
posite outcome of any recurrent cerebrovascular event. We
compared change in WMH by volume and visual scores and
tested WMH volume change for regression to the mean. For
display purposes and data summaries (but not statistical model-
ing), we divided WMH volume change into quintiles (Qs), from
greatest reduction (Q1) to greatest increase (Q5).
We used analysis of covariance (ANCOVA) to assess predic-
tors of follow-up WMH volume, including baseline vascular risk
factors. We adjusted for baseline WMH volume using the cube
root of the WMH volume normalized to ICV (i.e., percent
ICV) because this improved model fit. We also used a model
of changes16,17 in which the outcome variable is the difference
in WMH volume between baseline and 1 year and predictors are
differences in other variables, e.g., mean arterial BP. We used
multinomial logistic regression to assess the relationship between
1-year mRS score and WMH change. We tested whether WMH
change related to change in brain volume, baseline MD, or MD
change at 1 year and index stroke visible/not visible on DTI.
WMH change modeling retained direction of change (negative
or positive).
All available data were used in all analyses. Predictor variables
with strong relationships with other variables were removed
to minimize collinearity (estimated with variance inflation fac-
tors). We restricted predictor variables to 1 per 10 observations.18
We did not impute data. The p values are 2 sided.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the Lothian Ethics of
Medical Research Committee (REC 09/81101/54) and NHS
Lothian R1D Office (2009/W/NEU/14). All participants gave
written informed consent.
RESULTS Of 264 participants recruited, 190 had
MRI at baseline and 1 year and are the subject of
the current analysis. Of the 74 of 264 participants
not included in the present analysis, follow-up MRI
was not possible in 61 (22 were too unwell, 5 died, 34
declined) and was incomplete in 8, and 5 participants
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were not contactable (in all, 259 of 264 [98%] were
followed up). The 74 participants who did not have
MRI at 1 year were older but did not differ in pro-
portions with vascular risk factors, stroke subtype, or
baseline WMH volume from the 190 participants
with 1-year MRI.
The 190 included participants had a mean age of
65.3 years (SD6 11.3 years, range 34.3–96.9 years);
112 (59%) were male; and 87 (46%) had lacunar
ischemic stroke (table 1). The median time between
stroke and MRI was 4 days (interquartile range [IQR]
2–10 days); median NIHSS score was 1 (range 0–7);
139 of 190 (73%) had hypertension; mean arterial BP
was 102.8 6 15.4; 77 of 190 (41%) were current/
recent smokers; 15 of 190 (8%) had atrial fibrillation;
and 6 of 190 (3%) had 70% to 99% ipsilateral carotid
stenosis.
The mean baseline WMH volume was 21.96 6
24.84 mL (minimum 0 mL, maximum 121.48 mL,
or 1.45 6 1.57% of ICV); median WMH volume
was 12.56 mL (IQR 4.00–32.70 mL); and Fazekas
score was 2.5 of 6 (table 1). The mean WMH volume
Table 1 Baseline demographic features for all participants and by quintile of WMH change in 190 participants: Quintile 1, WMH decreased;
quintile 5, WMH increased the most; quintile 3, no overall WMH change
Baseline features by
p Value
Total Quintile of WMH change
(n 5 190) 1 2 3 4 5
Female, n (%) 78 (41) 14 (37) 16 (42) 15 (39) 18 (47) 15 (39) 0.91a
Age (mean 6 SD), y 65.3 6 11.3 72.1 6 8.3 63.3 6 10.8 62.5 6 11.8 61.1 6 9.9 67.5 6 11.9 ,0.001a
Cortical, n (%) 103 (54) 23 (61) 17 (45) 20 (53) 21 (55) 22 (58) 0.69
Lacunar, n (%) 87 (46) 15 (39) 21 (55) 18 (47) 17 (45) 16 (42)
Hypertensive, n (%) 142 (75) 32 (84) 31 (82) 27 (71) 24 (63) 28 (74) 0.22a
Mean BP (mean 6 SD), mm Hg 102.8 6 15.4 109.6 6 19.0 98.2 6 14.1 104 6 13.3 103.4 6 15.8 98.6 6 11.5 0.0064a
Current and <1 y ex-smoker, n (%) 73 (38) 10 (26) 17 (45) 14 (37) 17 (45) 15 (39) 0.45a
Hyperlipidemia, n (%) 116 (61) 26 (68) 23 (61) 26 (68) 19 (50) 22 (58) 0.43a
Diabetes mellitus, n (%) 21 (11) 10 (26) 2 (5) 1 (3) 6 (16) 2 (5) 0.006a
WMH (Fazekas) score, n (%)
0 8 (4) 0 (0) 2 (5) 3 (8) 3 (8) 0 (0) 0.0011c
1 17 (9) 1 (3) 3 (8) 7 (18) 6 (16) 0 (0)
2 70 (37) 8 (21) 18 (47) 15 (39) 16 (42) 13 (34)
3 24 (13) 4 (11) 5 (13) 4 (11) 4 (11) 7 (18)
4 29 (15) 8 (21) 7 (18) 5 (13) 3 (8) 6 (16)
5 17 (9) 6 (16) 3 (8) 0 (0) 4 (11) 4 (11)
6 25 (13) 11 (29) 0 (0) 4 (11) 2 (5) 8 (21)
Other imaging variables
WMH MD, mean (SD)b 1.001 (0.092) 0.989 (0.086) 0.988 (0.094) 0.996 (0.103) 1.011 (0.097) 1.025 (0.078) 0.060
WMH FA, mean (SD) 0.226 (0.043) 0.255 (0.025) 0.219 (0.043) 0.219 (0.040) 0.208 (0.052) 0.231 (0.038) ,0.001
NAWM MD, mean (SD)b 0.781 (0.030) 0.797 (0.025) 0.781 (0.030) 0.772 (0.032) 0.770 (0.027) 0.786 (0.027) 0.0007
NAWM FA mean (SD) 0.258 (0.023) 0.247 (0.021) 0.264 (0.026) 0.260 (0.025) 0.260 (0.019) 0.256 (0.018) 0.024
ICV mean (SD), mL 1480 (148) 1520 (169) 1474 (122) 1457 (156) 1473 (156) 1478 (130) 0.42
Brain volume, mean (SD), mL 1193 (128) 1179 (121) 1200 (109) 1192 (121) 1198 (165) 1198 (124) 0.95
Brain volume, mean (SD), %ICV 80.7 (5.0) 77.8 (4.9) 81.5 (4.7) 82.0 (4.2) 81.2 (5.4) 81.1 (5.0) 0.0016
WMH volume, mean (SD), mL 22.0 (24.8) 45.9 (32.4) 15.8 (14.6) 14.9 (22.5) 10.1 (12.2) 23.2 (20.4) ,0.001
WMH, mean (SD), %ICV 1.45 (1.57) 2.94 (1.94) 1.08 (1.01) 0.96 (1.32) 0.70 (0.86) 1.59 (1.44) ,0.001
Abbreviations: BP 5 blood pressure; FA 5 fractional anisotropy; ICV 5 intracranial volume; MD 5 mean diffusivity; NAWM 5 normal-appearing white
matter; WMH 5 white matter hyperintensity.
a The p value for variation in the characteristic being present vs absent (converse not shown) across the different quintiles.
bUnits for MD 5 31029 mm2/s.
c Based on Markov chain Monte Carlo computation because of violation of x2 assumptions (small expected numbers in the cells). The p values for categorical
variables use x2 test (df 5 4); p values for continuous data use F test (t test for .2 groups, df 5 4).
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at 1 year was 23.236 23.28 mL (minimum 0.8 mL,
maximum 121.56 mL), with a mean change of 1.27
6 8.46 mL overall (medianWMH volume 14.97 mL
[IQR, 5.86–32.74 mL], median change 1.42 mL
[IQR22.33 to 4.58 mL]). In multivariable modeling
to predict WMH volume at 1 year, without consid-
ering change in WMH from baseline, participants
with the most WMH at baseline had the most
WMH growth at 1 year (b 5 0.854 per baseline
WMH as percent ICV, 95% CI 0.781–0.927, p ,
0.0001, ANCOVA). Baseline WMH MD (b 5
0.077 per 1-unit difference in baseline MD, 95%
CI 0.022–0.133, p 5 0.007) and baseline mean BP
(b 5 20.0006 per 1-mm Hg higher baseline arterial
pressure, 95% CI 20.00099 to 20.00017, p 5
0.005) were also significant predictors of WMH vol-
ume at 1 year, which was inverse for BP.
WMH volume decreased by some degree in 71 of
190 participants (table 1). For display purposes, we
plotted WMH change in quintiles, from the greatest
WMH reduction in Q1 to the greatest increase in Q5
(figure 2). This revealed that although there was a wide
range of baseline WMH volumes in each change quin-
tile, in general, there was a U-shaped relationship
between baseline WMH and WMH change, with
the highest baseline WMH volumes being in Q1 and
Q5 and the lowest in Q3 and Q4 (p , 0.001, F test,
figure 3). The ranges of change inWMHwere231.97
to23.57 mL for Q1,23.55 to 0.59 mL for Q2, 0.71
to 2.21 mL for Q3, 2.36 to 5.76 mL for Q4, and
5.78 to 29.11 mL for Q5. However, on average, the
largest increases and decreases in WMH volumes
occurred in the middle range of baseline WMH values,
i.e.,z40 mL (figure e-1), providing little evidence of
regression to the mean. Age also showed a U-shaped
relationship with WMH volume change, the oldest par-
ticipants being in Q1 and Q5 (p, 0.001, F test, figure
3C and table 1). Mean baseline BP was highest in Q1
and lower in Q5 (p5 0.0064, F test, figure 3D). Many
of the 21 participants with diabetes mellitus were in Q1
(p 5 0.006). There were equal proportions with
a diagnosis of hypertension, with hyperlipidemia,
who smoked, and by stroke subtype per quintile.
Larger falls in mean arterial BP between baseline
and 1 year were associated with more WMH reduc-
tion (adjusted b 5 0.0053 percent ICV per 1 mm
Hg, 95% CI 0.00099–0.0097, p 5 0.017, table 2);
a similar pattern was seen for systolic and diastolic
BPs (figure e-2). There was no difference in pre-
scribed antihypertensive drug classes between WMH
quintiles (table e-2). There was no detectable associ-
ation with change in smoking habit.
Figure 2 Individual participants’ changes in WMH volume between baseline and 1 year by quintile of WMH
volume change
Each line represents an individual patient, linking baseline WMH volume (left) to follow-up WMH volume (right) of each quin-
tile column. WMH 5 white matter hyperintensities.
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At 1 year, 35 of 190 (18.4%) participants had any
recurrent cerebrovascular event (table e-3), which was
associated with WMH growth rather than reduction
(adjusted b5 0.27 WMH percent ICV per outcome
event, 95% CI 0.047–0.50, p 5 0.018, table 2).
Most participants were independent (167 of 190
[87.9%]) with no difference in mRS scores by
WMH change on univariate (p 5 0.99, table e-3)
or in adjusted analysis (table e-4).
To determine whether the WMH change was re-
flected in other tissue parameters (and therefore likely
to be real), we assessed associations with MD, brain
volume, visual WMH change scores, and visibility
of the index infarct on DTI at presentation. In
normal-appearing white matter, baseline MD and
fractional anisotropy showed a U-shaped relationship
with WMH change (p 5 0.0007, table 1). Between
baseline and 1 year, the MD changed significantly
with WMH change in both WMH (b 5 20.027
percent ICV, 95% CI 20.037 to 20.017, p ,
0.0001) and normal-appearing white matter (b 5
0.075 percent ICV, 95% CI 0.0025–0.15, p 5
0.043, table 2). Brain volume appeared to decrease
more in Q1 than in Q4 and Q5 between baseline and
1 year (figure e-3). Brain volume at 1 year was asso-
ciated with WMH change when baseline brain vol-
ume was not considered (ANCOVA, b5 0.34, 95%
CI 0.053–0.63, p 5 0.020) but became nonsignifi-
cant when corrected for baseline brain volume (b 5
0.14, 95% CI 20.098 to 0.38, p 5 0.25), although
the direction of effect remained the same. All reduc-
tions in WMH visual change scores were in Q1
through Q3, and most increases were in Q4 and
Q5 (figure e-4). There was no association between
visibility of the index infarct on DTI and WMH
change (figure e-5).
DISCUSSION We demonstrate some reduction in
WMH volume in participants presenting
with minor ischemic stroke that was associated with
fewer composite recurrent cerebrovascular events at
1 year and paralleled changes in other tissue parame-
ters compared with participants with WMH growth.
Thus, WMH may have some reversible component
that may be clinically meaningful, supporting the
concept that prevention of worsening WMH-related
brain damage may translate into long-term benefits
for brain health. While this observational study can-
not identify causality, the association of WMH
reduction with reduction in mean BP suggests that
better risk factor management not only might atten-
uate WMH growth but also may actually reverse
some WMH-related brain damage. The reduction in
MD of normal-appearing white matter as WMH
decreased could indicate improvements in white
matter integrity that could limit progressive brain
damage that leads to dementia.
Other factors, apart from decreasing BP, could
have influenced WMH reduction, e.g., other
Figure 3 WMH change according to (A) WMH volume at 1 year, (B) WMH volume
at baseline, (C) patient age, and (D) mean arterial blood pressure at
baseline
Participants in Q1 had the most WMH shrinkage and those in Q5 had the most WMH growth
between baseline and 1 year. In the box and whiskers, the central line is median, box lower
margin is 25th percentile, upper margin is 75th percentile, lower whisker is 5th percentile,
and upper whisker is 95th percentile. WMH vol 5 white matter hyperintensity volume.
Table 2 Multivariable modeling of factors associated with change in normalized
WMH volume (percent ICV per 1-unit change in predictor), follow-up minus
baseline
Predictor Estimate 95% CI VIF p Value
Change in WMH MDa 20.027 20.037 to 20.017 1.17 ,0.0001
Change in NAWM MDa 0.075 0.0025 to 0.15 1.22 0.043
Change in mean BP 0.0053 0.00099 to 0.0097 1.09 0.017
Recurrent cerebrovascular events at 1 y 0.27 0.047 to 0.50 1.03 0.018
Lacunar vs cortical 0.018 20.014 to 0.18 1.05 0.83
Baseline diabetic status 20.28 20.57 to 0.011 1.15 0.059
Baseline hypertensive diagnosis 0.041 20.14 to 0.22 1.08 0.65
Age (unit 5 5 y) 0.0027 20.038 to 0.043 1.27 0.90
Abbreviations: CI 5 confidence interval; MD 5 mean diffusivity; NAWM 5 normal-appearing
white matter; VIF 5 variance inflation factor; WMH 5 white matter hyperintensity.
aUnits for MD 5 31029 mm2/s.
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secondary prevention (statins) or lifestyle improve-
ments that participants might have adopted after
the warning stroke (smoking cessation, exercise, diet).
Although we did not find an effect of smoking cessa-
tion and were not able to assess changes in diabetes
control, diet, or exercise, these interventions showed
promise for reducing cognitive decline in community
participants.19 Alternatively, while numerous observa-
tional studies show associations between high BP and
WMH burden,20,21 randomized trials of BP reduction
have produced mixed results. This might reflect that
BP and hypertension account for only a small pro-
portion of WMH variance22 or that arterial stiffness is
key to WMH genesis rather than BP alone.23 There
was no obvious difference in prescribed antihyperten-
sive drug classes between the WMH change groups,
and it would be inappropriate to interpret any class-
quintile association as causative here. Future studies
should assess the effects of drug class on WMH
change and clinical outcomes.
WMH progression is related to baseline WMH
load; therefore, participants in Q1 and Q2 should
have had WMH progression similar to that in partic-
ipants in Q4 and Q5. That the reduction in WMH
volume is real, not artifact or regression to the mean
(figure e-1), is supported by changes in MD, brain
volume (figure 1 and figure e-3), and visual scores
(figure e-4). The reduction in brain volume as
WMH reduced is intriguing and suggests that inter-
stitial fluid reduces from the (possibly increased) state
at presentation with stroke, consistent with decreas-
ing MD of normal white matter (table 2). A similar
pattern of increased tissue fluid with increased brain
volume early in WMH development was described in
monogenic SVD.24
Most information on WMH longitudinal change
comes from community-based, relatively stable par-
ticipants, not patients with recent stroke whose brain
changes may be more dynamic. Most longitudinal
studies report no change or progression of WMH,3
but 4 community-based studies classified minor
WMH regression as no progression20,21 or measure-
ment error3 or did not discuss it.12 WMH regression
was noted in 1 case report4 and 14 of 100 (14%) pa-
tients with stroke.5 We used a very sensitive, well-
validated WMH volume method,7 as used in several
recent stroke or aging studies totaling several thousand
patients. We were careful to exclude all infarcts from the
WMH volume.14 That, plus use of a careful quality-
controlled magnetic resonance scanner, may have
increased the sensitivity to detect bidirectional WMH
changes. Future studies should assess tissue-level changes
in WMH that regress or grow to determine how to
identify lesions that are potentially reversible and scan
more frequently to determine the timing and rate of
change more precisely.
The study limitations include the complexities of
differentiating WMH volume from infarcts.14 We
manually differentiated index, old, and incident cor-
tical and subcortical infarcts, checked volumes, and
blinded all analyses. We cannot exclude that some
WMH reduction reflects regression to the mean,
but we do not think that all WMH changes (increases
or decreases) can be attributed solely to this because
both WMH increases and decreases occur along the
full range of WMH baseline volumes (figure e-1).
More scan-rescan studies are needed to determine
WMH variability. We did not have ambulatory BP
monitoring, but BP was measured carefully with val-
idated instruments. We obtained follow-up on 259 of
264 participants (98.1%), but 34 of 264 declined
repeat MRI (12.8%), which is low for a detailed
MRI study in which frail older participants may need
help attending hospital.
WMH pathogenesis is poorly understood. Lipo-
hyalinosis, arteriolosclerosis, and fibrinoid necrosis
describe perforating arteriolar wall damage, luminal
narrowing, and occlusion that could cause chronic
hypoperfusion and ischemia; blood-brain barrier
(endothelial) failure may lead to perivascular edema
and secondary brain damage.1,6,25 Multiple mecha-
nisms may contribute to WMH, including augmen-
tation. For example, leakage into the arteriolar wall
may cause thickening, luminal narrowing, decreased
vasoreactivity, and secondary ischemic damage super-
imposed on perivascular interstitial edema.1 The
reduction in MD in normal-appearing white matter
with WMH reduction suggests improved interstitial
fluid balance. White matter microstructural damage
precedes WMH appearance on MRI.26 Future studies
should assess microstructure in regions of WMH
growth and disappearance, with detailed cerebral
and systemic vascular function measures, to identify
mechanisms underlying WMH dynamics. WMH
reversibility, not just absence of progression, has
important consequences for identifying methods to
prevent long-term SVD-related brain damage.
WMH regression should be included in sample size
calculations for trials using WMH as an intermediary
endpoint. The possibility of minimizing deleterious
clinical effects of WMH should encourage greater
efforts to prevent vascular contributions to dementia.
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